Medicus Pharma shared details from its Q3 2026 earnings call, showing a $35.9 million loss this year.

Nov 9, 2026, 12:28 PM ETResultsRead the original at Benzinga

Neutral

Medicus reported a $35.9 million loss and higher costs, but its Pfizer deal and $42.5 million in equity and debt financing support development. The proposed Skinjet combination is not binding, so the report gives mixed signals.

MDCX · Medicus Pharma

AI read · Neutral

The AI's read

The Pfizer agreement gives Medicus worldwide rights to develop and sell a cancer drug, and Pfizer supplied $2 million for its development. The drug is still being tested and is not approved for sale. Medicus is also spending more and reported a large loss. Its $42.5 million financing came from equity and debt, and the proposed Skinjet deal is not binding. The call gives both support and ongoing financial strain, so it does not clearly change the company’s outlook.

PFE · Pfizer

AI read · Neutral

The connection

Pfizer joined the CD228V development deal and contributed $2 million. The call gives no expected sales or major business change for Pfizer, so its outlook is not changed by the report.

Get alerts for MDCX

Follow Medicus Pharma (MDCX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MDCX

Free on the App Store and Google Play, or on the web.